We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Arcus Biosciences
RCUS
$3.68B
| $369K | ﹤0.01% |
24,800
+2,500
| +11% | +$40.8K |
|
1402
Ingevity
NGVT
$2.61B
| $368K | ﹤0.01% |
9,037
+1,400
| +18% | +$58.3K |
|
1403
Xerox
XRX
$411M
| $367K | ﹤0.01% |
43,500
+10,400
| +31% | +$95.9K |
|
|
ARI
1404
Apollo Commercial Real Estate
ARI
$886M
| $366K | ﹤0.01% |
42,302
+6,000
| +17% | +$53.9K |
|
1405
Sylvamo
SLVM
$1.53B
| $363K | ﹤0.01% |
4,600
+300
| +7% | +$25.9K |
|
1406
Patrick Industries
PATK
$2.79B
| $362K | ﹤0.01% |
4,361
-1
| -0% | -$89 |
|
|
LADR
1407
Ladder Capital
LADR
$1.27B
| $361K | ﹤0.01% |
32,300
+5,000
| +18% | +$57.4K |
|
|
PGRE
1408
DELISTED
Paramount Group
PGRE
| $360K | ﹤0.01% |
72,920
| – | – |
|
|
INFA
1409
DELISTED
Informatica
INFA
| $359K | ﹤0.01% |
13,864
+100
| +0.7% | +$2.62K |
|
1410
Endava
DAVA
$163M
| $358K | ﹤0.01% |
11,600
-3,200
| -22% | -$87.6K |
|
|
AGNT
1411
AGNT Inc
AGNT
$722M
| $358K | ﹤0.01% |
31,100
| – | – |
|
|
SAFE
1412
Safehold
SAFE
$1.1B
| $356K | ﹤0.01% |
19,243
| – | – |
|
1413
Sprout Social
SPT
$580M
| $356K | ﹤0.01% |
11,600
+2,600
| +29% | +$78.2K |
|
1414
Radware
RDWR
$1.23B
| $354K | ﹤0.01% |
15,700
| – | – |
|
|
PYCR
1415
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $353K | ﹤0.01% |
19,000
+3,800
| +25% | +$63.4K |
|
1416
Perdoceo Education
PRDO
$2B
| $352K | ﹤0.01% |
13,300
| – | – |
|
1417
Utz Brands
UTZ
$1.25B
| $349K | ﹤0.01% |
22,300
+3,400
| +18% | +$57.5K |
|
|
ALEX
1418
DELISTED
Alexander & Baldwin
ALEX
| $348K | ﹤0.01% |
19,603
| – | – |
|
1419
PagerDuty
PD
$878M
| $347K | ﹤0.01% |
19,000
+2,100
| +12% | +$40.3K |
|
|
MCW
1420
DELISTED
Mister Car Wash
MCW
| $343K | ﹤0.01% |
47,100
+4,000
| +9% | +$29.2K |
|
|
B
1421
DELISTED
Barnes Group Inc.
B
| $343K | ﹤0.01% |
7,255
-3,100
| -30% | -$144K |
|
1422
Apogee Therapeutics
APGE
$10.2B
| $340K | ﹤0.01% |
7,500
-1,300
| -15% | -$66.3K |
|
1423
Lindsay Corp
LNN
$1.16B
| $340K | ﹤0.01% |
2,872
| – | – |
|
|
ELME
1424
Elme Communities
ELME
$145M
| $339K | ﹤0.01% |
22,183
| – | – |
|
1425
Leggett & Platt
LEG
$1.33B
| $335K | ﹤0.01% |
34,900
| – | – |
|
Similar funds
VIA
GAM
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.